A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis

References

• HarrTFrenchLEToxic epidermal necrolysis and Stevens-Johnson syndromeOrphanet J Rare Dis2010513921162721
   PubMed Web of Science ®Google Scholar
• AbeJUmetsuRMatakiKAnalysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report databaseJ Pharm Health Care Sci2016211427330825
   PubMedGoogle Scholar
• Bastuji-GarinSRzanyBSternRSClinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiformeArch Dermatol1993129192968420497
   PubMedGoogle Scholar
• SchwartzRAMcDonoughPHLeeBWToxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesisJ Am Acad Dermatol2013692173e123866878
   PubMed Web of Science ®Google Scholar
• SchneiderJACohenPRStevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measuresAdv Ther20173461235124428439852
   PubMed Web of Science ®Google Scholar
• LocharernkulCLoplumlertJLimotaiCCarbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B* 1502 allele in Thai populationEpilepsia200849122087209118637831
   PubMed Web of Science ®Google Scholar
• WhiteKDChungWHHungSIEvolving models of the immunopathogenesis of T cell–mediated drug allergy: the role of host, pathogens, and drug responseJ Allergy Clin Immunol2015136221923426254049
   PubMed Web of Science ®Google Scholar
• SchwartzRAMcDonoughPHLeeBWToxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatmentJ Am Acad Dermatol2013692187e123866879
   PubMed Web of Science ®Google Scholar
• ReeseDHenningJSRockersKCyclosporine for SJS/TEN: a case series and review of the literatureCutis 2018712429
   Web of Science ®Google Scholar
• KirchhofMGMiliszewskiMASikoraSRetrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporineJ Am Acad Dermatol201471594194725087214
   PubMed Web of Science ®Google Scholar
• SinghGKChatterjeeMVermaRCyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroidIndian J Dermatol Venereol Leprol201379568623974585
   PubMed Web of Science ®Google Scholar
• KumaPKanti DasNCyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modalityDermatol Online J20162210
   Google Scholar
• MéndezAMonforteVBerasteguiCHigh intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosisClin Transplant201428674374824708188
   PubMed Web of Science ®Google Scholar
• ZimmermannSSekulaPVenhoffMSystemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisJAMA Dermatol2017153651452228329382
   PubMed Web of Science ®Google Scholar
• FouchardNBertocchiMRoujeauJCSCORTEN: a severity-of-illness score for toxic epidermal necrolysisJ Invest Dermatol2000115214915310951229
   PubMed Web of Science ®Google Scholar
• GueganSBastuji-GarinSPoszepczynska-GuignéEPerformance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysisJ Invest Dermatol2006126227227616374461
   PubMed Web of Science ®Google Scholar
• ArévaloJMLorenteJAGonzález-HerradaCJiménez-ReyesJTreatment of toxic epidermal necrolysis with cyclosporin AJ Trauma Acute Care Surg2000483473478
   Google Scholar
• FirozBFHenningJSZarzabalLAPollockBHToxic epidermal necrolysis: five years of treatment experience from a burn unitJ Am Acad Dermatol201267463063522285617
   PubMed Web of Science ®Google Scholar
• GiudiceGMaggioGBufanoLManagement of toxic epidermal necrolysis with plasmapheresis and cyclosporine A: our 10 years’ experiencePlast Reconstr Surg Glob Open201752e122128280663
   PubMedGoogle Scholar
• González-HerradaCRodríguez-MartínSCachafeiroLCiclosporin use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approachesJ Invest Dermatol2017137102092210028634032
   PubMed Web of Science ®Google Scholar
• LeeHYFook-ChongSKohHYCyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral centerJ Am Acad Dermatol201776110611327717620
   PubMed Web of Science ®Google Scholar
• MohantySDasAGhoshAEffectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson sndrome/toxic epidermal necrolysis: a record-based studyIndian J Dermatol Venereol Leprol201783331228366923
   PubMed Web of Science ®Google Scholar
• RajaratnamRMannCBalasubramaniamPToxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centreClin Exp Dermatol201035885386220456393
   PubMed Web of Science ®Google Scholar
• SzepietowskiJWa̧sikFSzybejko-MachajGMajJToxic epidermal necrolysis successfully treated with cyclosporin. Report of three casesJ Eur Acad Dermatol Venereol199792169172
   Web of Science ®Google Scholar
• Valeyrie-AllanoreLWolkensteinPBrochardLOpen trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysisBr J Dermatol2010163484785320500799
   PubMed Web of Science ®Google Scholar
• SternRSDivitoSJStevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology – thirty years of progress but still much to be doneJ Invest Dermatol201713751004100828411832
   PubMed Web of Science ®Google Scholar
• ChungWHHungSIYangJYGranulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysisNat Med200814121343135019029983
   PubMed Web of Science ®Google Scholar
• AmorKTRyanCMenterAThe use of cyclosporine in dermatology: part IJ Am Acad Dermatol201063692594621093659
   PubMed Web of Science ®Google Scholar
• RemickDGNguyenDTEskandariMKCyclosporine A inhibits TNF production without decreasing TNF mRNA levelsBiochem Biophys Res Commun198916125515552735909
   PubMed Web of Science ®Google Scholar
• LebwohlMEllisCGottliebACyclosporine consensus conference: with emphasis on the treatment of psoriasisJ Am Acad Dermatol19983934644759738783
   PubMed Web of Science ®Google Scholar
• PalestineAGNussenblattRBChanCCSide effects of systemic cyclosporine in patients not undergoing transplantationAm J Med19847746526566486141
   PubMed Web of Science ®Google Scholar
• JacobsonSKCalneRYWreghittTGOutcome of HIV infection in transplant patient on cyclosporinLancet19913378744794
   Web of Science ®Google Scholar